- Home
- IKT vs GNLX Comparison
IKT vs GNLX Comparison
Compare IKT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- GNLX
- Stock Information
- Founded
- IKT 2008
- GNLX 2001
- Country
- IKT United States
- GNLX United States
- Employees
- IKT N/A
- GNLX N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- IKT Health Care
- GNLX Health Care
- Exchange
- IKT Nasdaq
- GNLX Nasdaq
- Market Cap
- IKT 140.5M
- GNLX 112.5M
- IPO Year
- IKT 2020
- GNLX 2023
- Fundamental
- Price
- IKT $1.85
- GNLX $3.44
- Analyst Decision
- IKT Buy
- GNLX Strong Buy
- Analyst Count
- IKT 2
- GNLX 4
- Target Price
- IKT $8.00
- GNLX $17.75
- AVG Volume (30 Days)
- IKT 526.2K
- GNLX 152.2K
- Earning Date
- IKT 08-13-2025
- GNLX 08-13-2025
- Dividend Yield
- IKT N/A
- GNLX N/A
- EPS Growth
- IKT N/A
- GNLX N/A
- EPS
- IKT N/A
- GNLX N/A
- Revenue
- IKT N/A
- GNLX N/A
- Revenue This Year
- IKT N/A
- GNLX N/A
- Revenue Next Year
- IKT N/A
- GNLX N/A
- P/E Ratio
- IKT N/A
- GNLX N/A
- Revenue Growth
- IKT N/A
- GNLX N/A
- 52 Week Low
- IKT $1.12
- GNLX $1.60
- 52 Week High
- IKT $4.20
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- IKT 47.71
- GNLX 65.71
- Support Level
- IKT $1.80
- GNLX $2.80
- Resistance Level
- IKT $2.09
- GNLX $3.61
- Average True Range (ATR)
- IKT 0.14
- GNLX 0.22
- MACD
- IKT 0.03
- GNLX 0.05
- Stochastic Oscillator
- IKT 54.72
- GNLX 80.23
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.